Cargando…
Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review
Acute myeloid leukemia (AML) is a hematological malignancy commonly found in adult patients. Low overall survival and resistance to therapy are the main issues in AML. The first line of treatment for AML chemotherapy is the induction phase, namely, the phase to induce remission by administering a co...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885730/ https://www.ncbi.nlm.nih.gov/pubmed/36726936 http://dx.doi.org/10.7759/cureus.33165 |
_version_ | 1784879990994632704 |
---|---|
author | Arwanih, Elly Y Louisa, Melva Rinaldi, Ikhwan Wanandi, Septelia I |
author_facet | Arwanih, Elly Y Louisa, Melva Rinaldi, Ikhwan Wanandi, Septelia I |
author_sort | Arwanih, Elly Y |
collection | PubMed |
description | Acute myeloid leukemia (AML) is a hematological malignancy commonly found in adult patients. Low overall survival and resistance to therapy are the main issues in AML. The first line of treatment for AML chemotherapy is the induction phase, namely, the phase to induce remission by administering a combination of daunorubicin (DNR) for three days followed by administration of cytarabine (Ara-C) with continuous infusion for seven days, which is referred to as "3 + 7." Such induction therapy has been the standard therapy for AML for the last four decades. This review article is made to discuss daunorubicin and cytarabine from their chemical structure, pharmacodynamics, pharmacokinetics, and mechanisms of resistance in AML. |
format | Online Article Text |
id | pubmed-9885730 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-98857302023-01-31 Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review Arwanih, Elly Y Louisa, Melva Rinaldi, Ikhwan Wanandi, Septelia I Cureus Internal Medicine Acute myeloid leukemia (AML) is a hematological malignancy commonly found in adult patients. Low overall survival and resistance to therapy are the main issues in AML. The first line of treatment for AML chemotherapy is the induction phase, namely, the phase to induce remission by administering a combination of daunorubicin (DNR) for three days followed by administration of cytarabine (Ara-C) with continuous infusion for seven days, which is referred to as "3 + 7." Such induction therapy has been the standard therapy for AML for the last four decades. This review article is made to discuss daunorubicin and cytarabine from their chemical structure, pharmacodynamics, pharmacokinetics, and mechanisms of resistance in AML. Cureus 2022-12-31 /pmc/articles/PMC9885730/ /pubmed/36726936 http://dx.doi.org/10.7759/cureus.33165 Text en Copyright © 2022, Arwanih et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Arwanih, Elly Y Louisa, Melva Rinaldi, Ikhwan Wanandi, Septelia I Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review |
title | Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review |
title_full | Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review |
title_fullStr | Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review |
title_full_unstemmed | Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review |
title_short | Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review |
title_sort | resistance mechanism of acute myeloid leukemia cells against daunorubicin and cytarabine: a literature review |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885730/ https://www.ncbi.nlm.nih.gov/pubmed/36726936 http://dx.doi.org/10.7759/cureus.33165 |
work_keys_str_mv | AT arwanihellyy resistancemechanismofacutemyeloidleukemiacellsagainstdaunorubicinandcytarabinealiteraturereview AT louisamelva resistancemechanismofacutemyeloidleukemiacellsagainstdaunorubicinandcytarabinealiteraturereview AT rinaldiikhwan resistancemechanismofacutemyeloidleukemiacellsagainstdaunorubicinandcytarabinealiteraturereview AT wanandisepteliai resistancemechanismofacutemyeloidleukemiacellsagainstdaunorubicinandcytarabinealiteraturereview |